Lead party: Austell Pharmaceuticals Proprietary Limited (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: Dezzo Trading 392 (Pty) Ltd (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: South Africa
Transaction type: Merger/Acquisition(M&A) · Asset class: Corporate Transactions · Strategy: Carve-Out · Instrument: Equity · Deal amount: US$1.5m · Equity stake: 1% · Implied EV: US$1.5m
Lead investor/buyer: Austell Pharmaceuticals Proprietary Limited · Investors/buyers: Austell Pharmaceuticals Proprietary Limited
Legal advisers: not identified in the source record.
Source: announced 21 September 2020. Original announcement: ascendishealth.com.


